Alvotech Stock In Focus After Europe Filing For Eylea 8 Mg Copycat

Alvotech and Advanz Pharma previously submitted a European regulatory application for AVT29, a proposed biosimilar to Eylea 8 mg, as a line extension to the approved Mynzepli marketing authorization. This marked the first reported global filing targeting the higher dose aflibercept formulation. The move shifts Alvotech’s eye care portfolio toward the 8 mg Eylea segment, which recently represented about 57% of combined global Eylea 2 mg and 8 mg sales by value. This points to a focus on...